• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

STAT3 表达激活 EGFR 驱动的肺腺癌。

STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.

机构信息

Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.

出版信息

Lung Cancer. 2012 Jan;75(1):24-9. doi: 10.1016/j.lungcan.2011.05.015.

DOI:10.1016/j.lungcan.2011.05.015
PMID:21684622
Abstract

Bronchioloalveolar carcinoma (BAC) pattern is often seen at the margin of invasive adenocarcinomas. We investigated EGFR signaling abnormalities involved in the progression of adenocarcinoma. Fifty tumors were obtained from patients who underwent surgery for lung adenocarcinoma seen as dense areas in ground glass opacity on computed tomography. Six, 18, and 26 tumors <1cm, 1-2 cm, and ≥2 cm in diameter, respectively, were analyzed. Of the 24 tumors ≤2 cm in diameter, nine were preinvasive and 15 were invasive. EGFR, pAKT, and pMAPK were overexpressed in the center of the adenocarcinoma compared to the BAC component (p<0.01) by immunohistochemistry, while pSTAT3 expression was reversed (p=0.017). In the tumors ≤2 cm in diameter, pSTAT3 expression in the central area was higher in preinvasive tumors than in invasive tumors (p=0.005). pSTAT3 was identified in the BAC component of 88% of the EGFR mutant (n=17) and 82% of the wild-type tumors (n=33). Transgenic mice expressing delE748-A752 EGFR and two lung cancer cell lines (PC-9 mutant and A549 wild-type EGFR) were also investigated. In transgenic mice, pSTAT3 was overexpressed in the BAC component around the adenocarcinoma center. Two lung cancer cell lines that overexpressed pSTAT3 were equally sensitive to a JAK2/STAT3 inhibitor (JSI-124). The role of STAT3 in the progression of adenocarcinoma should be further pursued.

摘要

细支气管肺泡癌(BAC)模式通常见于浸润性腺癌的边缘。我们研究了涉及腺癌进展的 EGFR 信号异常。从因 CT 显示毛玻璃密度阴影而接受肺癌手术的患者中获得了 50 个肿瘤。分别分析了直径<1cm、1-2cm 和≥2cm 的 6、18 和 26 个肿瘤。在直径≤2cm 的 24 个肿瘤中,9 个为前驱病变,15 个为浸润性肿瘤。免疫组化显示,与 BAC 成分相比,腺癌中心的 EGFR、pAKT 和 pMAPK 表达过度(p<0.01),而 pSTAT3 表达相反(p=0.017)。在直径≤2cm 的肿瘤中,前驱病变中心区域的 pSTAT3 表达高于浸润性肿瘤(p=0.005)。在 EGFR 突变(n=17)和野生型肿瘤(n=33)的 88%和 82%的肿瘤中,都在 BAC 成分中发现了 pSTAT3。还研究了表达 delE748-A752 EGFR 的转基因小鼠和两种肺癌细胞系(PC-9 突变型和 A549 野生型 EGFR)。在转基因小鼠中,pSTAT3 在腺癌中心周围的 BAC 成分中过度表达。两种过度表达 pSTAT3 的肺癌细胞系对 JAK2/STAT3 抑制剂(JSI-124)同样敏感。STAT3 在腺癌进展中的作用值得进一步研究。

相似文献

1
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.STAT3 表达激活 EGFR 驱动的肺腺癌。
Lung Cancer. 2012 Jan;75(1):24-9. doi: 10.1016/j.lungcan.2011.05.015.
2
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.表皮生长因子受体(EGFR)激酶结构域中的突变通过在人肺腺癌中产生白细胞介素-6(IL-6)来介导信号转导和转录激活因子3(STAT3)的激活。
J Clin Invest. 2007 Dec;117(12):3846-56. doi: 10.1172/JCI31871.
3
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.表皮生长因子受体(EGFR)突变的非小细胞肺癌中信号转导及转录激活因子3(STAT3)与Yes相关蛋白1(YAP1)通路的共激活
J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.
4
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.在切除的肺腺癌中,EGFR 和 KRAS 突变并未富集 IL-6、JAK1 或磷酸化 STAT3 的激活。
Med Oncol. 2017 Sep 6;34(10):175. doi: 10.1007/s12032-017-1031-1.
5
High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.韩国男性吸烟肺腺癌患者中 EGFR 突变的高发率:与组织学亚型、EGFR/TTF-1 表达及临床特征的相关性,无肿瘤内异质性。
J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.
6
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.腺癌中具有细支气管肺泡癌成分的表皮生长因子受体的遗传进化。
Clin Lung Cancer. 2010 May;11(3):160-8. doi: 10.3816/CLC.2010.n.020.
7
Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.在肺小腺癌的多阶段进展过程中表皮生长因子受体突变和 p53 过表达。
J Thorac Oncol. 2010 Jul;5(7):964-9. doi: 10.1097/JTO.0b013e3181dd15c0.
8
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.在早期肺腺癌的侵袭前沿,Cox-2与层粘连蛋白-5γ2链频繁共定位。
Am J Pathol. 2002 Mar;160(3):1129-41. doi: 10.1016/s0002-9440(10)64933-4.
9
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.肺腺癌全基因组分析确定II型转化生长因子-β受体为侵袭性的抑制因子。
Am J Respir Crit Care Med. 2005 Sep 15;172(6):729-37. doi: 10.1164/rccm.200504-615OC. Epub 2005 Jun 23.
10
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.细支气管肺泡癌和腺癌(细支气管肺泡癌亚型)的分子特征可预测对厄洛替尼的反应。
J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062.

引用本文的文献

1
Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies.肺癌炎性肿瘤微环境中的旁分泌调节与免疫系统通路:对肿瘤发生及免疫治疗策略的见解
Cancers (Basel). 2024 Mar 10;16(6):1113. doi: 10.3390/cancers16061113.
2
Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.携带上皮生长因子受体突变且微小RNA - 135b过表达的外周型肺腺癌更易侵犯脏层胸膜。
Oncol Lett. 2017 Dec;14(6):7931-7940. doi: 10.3892/ol.2017.7195. Epub 2017 Oct 16.
3
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
在切除的肺腺癌中,EGFR 和 KRAS 突变并未富集 IL-6、JAK1 或磷酸化 STAT3 的激活。
Med Oncol. 2017 Sep 6;34(10):175. doi: 10.1007/s12032-017-1031-1.
4
Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.在一家机构切除的浸润性肺腺癌中表皮生长因子受体(EGFR)以及磷脂酰肌醇-3激酶/蛋白激酶B(PI3K/Akt)、Raf-1-丝裂原活化蛋白激酶/细胞外信号调节激酶激酶1/2(MEK-1-MAP,Erk1/2)和Janus激酶(JAK,信号转导子和转录激活子3,STAT3)信号通路下游分子的表达情况
Anal Cell Pathol (Amst). 2014;2014:352925. doi: 10.1155/2014/352925. Epub 2014 Dec 18.
5
Epidermal growth factor receptor mutations in lung adenocarcinoma.肺腺癌中的表皮生长因子受体突变。
Lab Invest. 2014 Feb;94(2):129-37. doi: 10.1038/labinvest.2013.147. Epub 2013 Dec 30.
6
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.苯乙基异硫氰酸酯在 HER2 阳性乳腺癌模型中的抗肿瘤活性。
BMC Med. 2012 Jul 24;10:80. doi: 10.1186/1741-7015-10-80.
7
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.JAK2 相关通路诱导携带表皮生长因子受体激活突变的肺癌细胞获得厄洛替尼耐药性。
Cancer Sci. 2012 Oct;103(10):1795-802. doi: 10.1111/j.1349-7006.2012.02363.x. Epub 2012 Jul 24.